drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous gene-modified T lymphocytes expressing a chimeric antigen receptor targeting GPRC5D; binding to GPRC5D on myeloma cells triggers T-cell activation, expansion, and cytotoxic killing. Administered after lymphodepleting chemotherapy in relapsed/refractory multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that recognizes GPRC5D on myeloma cells. CAR engagement activates T‑cell signaling, leading to expansion and targeted cytotoxicity (perforin/granzyme release and cytokine-mediated killing) of GPRC5D‑positive malignant plasma cells following lymphodepleting chemotherapy.
drug_name
Anti-GPRC5D CAR-T cells
nct_id_drug_ref
NCT05739188